1%伏立康唑滴眼液吸收与清除的开放标签研究。
Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops.
作者信息
Neoh Chin Fen, Leung Lok, Chan Elsie, Al-Badriyeh Daoud, Fullinfaw Robert O, Jhanji Vishal, Vajpayee Rasik B, Davies Geoffrey E, Stewart Kay, Kong David C M
机构信息
Collaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
出版信息
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6896-6898. doi: 10.1128/AAC.00683-16. Print 2016 Nov.
Abstract
Twenty participants undergoing elective cataract surgery received 1% voriconazole eye drops (1 drop per eye) either 20, 40, 60, or 80 min before surgery. Median voriconazole concentrations of 1.9 to 3.2 mg/liter in aqueous humor samples were attained over the first 80 min, which were higher than in vitro MIC values for typical fungi that cause keratitis.
摘要
20名接受择期白内障手术的参与者在手术前20、40、60或80分钟接受1%伏立康唑滴眼液（每只眼睛滴1滴）。在最初的80分钟内，房水样本中伏立康唑的中位浓度达到1.9至3.2毫克/升，高于引起角膜炎的典型真菌的体外最低抑菌浓度值。
相似文献
1
Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops.1%伏立康唑滴眼液吸收与清除的开放标签研究。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6896-6898. doi: 10.1128/AAC.00683-16. Print 2016 Nov.
2
Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study.1%伏立康唑滴眼液在人房水中的渗透：一项前瞻性开放标签研究。
Arch Ophthalmol. 2008 Mar;126(3):343-6. doi: 10.1001/archophthalmol.2007.71.
3
Prospective open-label study of the administration of two-percent voriconazole eye drops.2%伏立康唑滴眼液给药的前瞻性开放标签研究。
Antimicrob Agents Chemother. 2009 Jul;53(7):3153-5. doi: 10.1128/AAC.01700-08. Epub 2009 May 11.
4
Penetration of 1% voriconazole eye drops into human vitreous humour: a prospective, open-label study.1%伏立康唑滴眼液在人玻璃体液中的渗透：一项前瞻性、开放标签研究。
Clin Exp Ophthalmol. 2009 Mar;37(2):197-200. doi: 10.1111/j.1442-9071.2008.01911.x. Epub 2008 Dec 29.
5
Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application.比较局部应用 1%伏立康唑后未刮除和刮除角膜上皮组房水和玻璃体内伏立康唑浓度。
Curr Eye Res. 2010 Jul;35(7):573-9. doi: 10.3109/02713681003760135.
6
Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye.局部应用的环丙沙星、诺氟沙星和氧氟沙星在未发炎人眼房水中的渗透情况。
J Chemother. 1997 Aug;9(4):257-62. doi: 10.1179/joc.1997.9.4.257.
7
Corneal Pharmacokinetics of Voriconazole and Posaconazole following Intrastromal Injection and Posaconazole Eye Drops Instillation in Rats.角膜中伏立康唑和泊沙康唑经皮注射和滴眼后在大鼠体内的药代动力学研究。
Curr Eye Res. 2020 Nov;45(11):1369-1372. doi: 10.1080/02713683.2020.1749669. Epub 2020 Apr 23.
8
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.局部或局部与全身联合给药治疗真菌性角膜炎时人房水和血浆中的伏立康唑浓度。
Antimicrob Agents Chemother. 2007 Jan;51(1):239-44. doi: 10.1128/AAC.00762-06. Epub 2006 Oct 23.
9
Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.白内障手术患者中莫西沙星 0.5%眼用溶液和贝西沙星 0.6%眼用混悬液的水透过率。
J Cataract Refract Surg. 2010 Sep;36(9):1499-502. doi: 10.1016/j.jcrs.2010.04.030.
10
[Aqueous humor concentration of norfloxacin following local administration].
Ophthalmologica. 1991;202(4):213-6. doi: 10.1159/000310204.
引用本文的文献
1
First Isolation of a Multi-azole-Resistant Aspergillus fumigatus cyp51A TR/Y46F/F70L Mutant in a Patient with Fungal Keratitis.在一名真菌性角膜炎患者中首次分离出对多种唑类耐药的烟曲霉cyp51A TR/Y46F/F70L突变体。
Mycopathologia. 2025 Sep 11;190(5):83. doi: 10.1007/s11046-025-00993-z.
2
Augmented glycerosomes as a promising approach against fungal ear infection: Optimization and microbiological, and assessments.增强型甘油脂质体作为一种对抗耳部真菌感染的有前景的方法：优化及微生物学和评估
Int J Pharm X. 2024 Oct 22;8:100295. doi: 10.1016/j.ijpx.2024.100295. eCollection 2024 Dec.
3
Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.英国角膜和隐形眼镜真菌分离株的抗真菌药敏谱。
Eye (Lond). 2024 Feb;38(3):529-536. doi: 10.1038/s41433-023-02719-1. Epub 2023 Sep 8.
4
Oral voriconazole monotherapy for fungal keratitis: efficacy, safety, and factors associated with outcomes.口服伏立康唑单药治疗真菌性角膜炎：疗效、安全性及与预后相关的因素。
Front Med (Lausanne). 2023 May 11;10:1174264. doi: 10.3389/fmed.2023.1174264. eCollection 2023.
5
Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.通过非常规方法递送的用于侵袭性感染的传统抗真菌药物；气雾剂、冲洗剂、定向注射剂和浸渍骨水泥。
J Fungi (Basel). 2022 Feb 21;8(2):212. doi: 10.3390/jof8020212.
6
Drug reservoir function of voriconazole impregnated human amniotic membrane: An study.载有伏立康唑的人羊膜的药物储存功能：一项研究。
Indian J Ophthalmol. 2021 May;69(5):1068-1072. doi: 10.4103/ijo.IJO_2649_20.
7
Physical, chemical, and microbiological stability study of diluted atropine eye drops.稀释阿托品滴眼液的物理、化学和微生物稳定性研究。
J Pharm Health Care Sci. 2019 Dec 5;5:25. doi: 10.1186/s40780-019-0154-2. eCollection 2019.
8
Successful treatment of keratitis with voriconazole.伏立康唑成功治疗角膜炎。
Int Med Case Rep J. 2017 Mar 20;10:93-95. doi: 10.2147/IMCRJ.S131372. eCollection 2017.
本文引用的文献
1
Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis.伏立康唑滴眼液治疗真菌性角膜炎的设计与评价
J Pharm (Cairo). 2014;2014:490595. doi: 10.1155/2014/490595. Epub 2014 Apr 29.
2
Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial.在一项随机试验中对局部用1%伏立康唑和5%那他霉素治疗真菌性角膜炎的重新评估。
Br J Ophthalmol. 2015 Sep;99(9):1190-5. doi: 10.1136/bjophthalmol-2014-306485. Epub 2015 Mar 4.
3
Clinical utility of caspofungin eye drops in fungal keratitis.卡泊芬净滴眼液在真菌性角膜炎中的临床应用。
Int J Antimicrob Agents. 2014 Aug;44(2):96-104. doi: 10.1016/j.ijantimicag.2014.04.008. Epub 2014 May 17.
4
Pharmacoeconomics of voriconazole in the management of invasive fungal infections.伏立康唑治疗侵袭性真菌感染的药物经济学评价。
Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):623-36. doi: 10.1586/erp.10.69.
5
Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans.单剂量和多剂量眼部药代动力学和局部伏立康唑临时制剂在人体中的稳定性分析。
Curr Eye Res. 2010 Nov;35(11):953-60. doi: 10.3109/02713683.2010.506968.
6
Stability of extemporaneously prepared voriconazole ophthalmic solution.临时配制的伏立康唑滴眼液的稳定性。
Am J Health Syst Pharm. 2009 Aug 15;66(16):1478-83. doi: 10.2146/ajhp080110.
7
Prospective open-label study of the administration of two-percent voriconazole eye drops.2%伏立康唑滴眼液给药的前瞻性开放标签研究。
Antimicrob Agents Chemother. 2009 Jul;53(7):3153-5. doi: 10.1128/AAC.01700-08. Epub 2009 May 11.
8
Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study.1%伏立康唑滴眼液在人房水中的渗透：一项前瞻性开放标签研究。
Arch Ophthalmol. 2008 Mar;126(3):343-6. doi: 10.1001/archophthalmol.2007.71.
9
Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.人类局部应用1%伏立康唑后的房水和玻璃体浓度。
Arch Ophthalmol. 2008 Jan;126(1):18-22. doi: 10.1001/archophthalmol.2007.8.
10
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.局部或局部与全身联合给药治疗真菌性角膜炎时人房水和血浆中的伏立康唑浓度。
Antimicrob Agents Chemother. 2007 Jan;51(1):239-44. doi: 10.1128/AAC.00762-06. Epub 2006 Oct 23.
Zotero 插件